8POJ image
Entry Detail
PDB ID:
8POJ
Title:
TEAD2 in complex with an inhibitor
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-07-05
Release Date:
2023-11-22
Method Details:
Experimental Method:
Resolution:
2.45 Å
R-Value Free:
0.26
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Transcriptional enhancer factor TEF-4
Chain IDs:A (auth: B), B (auth: A)
Chain Length:240
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.
Bioorg.Med.Chem.Lett. 95 129488 129488 (2023)
PMID: 37770003 DOI: 10.1016/j.bmcl.2023.129488

Abstact

The Hippo pathway regulates organ size and tissue homeostasis by controlling cell proliferation and apoptosis. The YAP-TEAD transcription factor, the downstream effector of the Hippo pathway, regulates the expression of genes such as CTGF, Cyr61, Axl and NF2. Aberrant Hippo activity has been identified in multiple types of cancers. Flufenamic acid (FA) was reported to bind in a liphophilic TEAD palmitic acid (PA) pocket, leading to reduction of the expression of Axl and NF2. Here, we show that the replacement of the trifluoromethyl moiety in FA by aromatic groups, directly connected to the scaffold or separated by a linker, leads to compounds with better affinity to TEAD. Co-crystallization studies show that these compounds bind similarly to FA, but deeper within the PA pocket. Our studies identified LM-41 and AF-2112 as two TEAD binders that strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 gave the strongest reduction of migration of human MDA-MB-231 breast cancer cells.

Legend

Protein

Chemical

Disease

Primary Citation of related structures